Philip Bath

British clinician scientist

Philip Bath

FRCP FMedSci

Born|  (1956-10-07) 7 October 1956 (age 68)

Venezuela

Nationality| British
Education| GKT School of Medical Education
Occupation(s)| Stroke physician, clinical researcher, academic
Medical career
Institutions|

* King's College London
* St George's, University of London
* University of Nottingham
* Nottingham University Hospitals NHS Trust

Sub-specialties|

* General medicine
* stroke
* clinical pharmacology

Research|

* stroke
* hypertension
* clinical trial

Philip Michael Bath FRCP FMedSci (born 7 October 1956) is a British clinician scientist. He is Stroke Association Professor of Stroke Medicine at the Stroke Trials Unit [1] within the University of Nottingham. He specialises clinically in stroke and academically has established large-scale trials in treating and preventing stroke. Bath worked as a junior doctor before specialising in general medicine, stroke and hypertension. He is an Honorary Consultant Physician at Nottingham University Hospitals NHS Trust. He has spent his academic career at St George's, University of London, King's College London and University of Nottingham.

## Early life and education

[edit]

Bath was educated at Dulwich College in London, U.K. and studied medicine at St Thomas's Hospital Medical School, now GKT School of Medical Education. graduating with a Bachelor of Science (BSc) degree in Physiology in 1979, and Bachelor of Medicine, Bachelor of Surgery (MB BS) in 1982. He undertook research for a Doctor of Medicine (M.D.) degree, completing it in 1992 and winning the Rogers prize at University of London. His thesis was titled "Human monocyte behaviour and interactions with endothelium : aspects of physiology and pathology".[2] He was awarded his Doctor of Science (D.Sc.) from the University of Nottingham in 2015, entitled "Management of blood pressure after stroke".[3]

## Career

[edit]

Having worked as a junior doctor, Bath specialised in internal medicine. In 1986 he became a Member of the Royal Colleges of Physicians of the United Kingdom (MRCP), and in 1998 a Fellow of the Royal College of Physicians (FRCP). From 1991 to 1993, Bath was a lecturer at the Blood Pressure Unit at St George's, University of London where he worked for the distinguished hypertensionologist, Professor Graham MacGregor. He moved in 1993 to King's College Hospital Medical School, London, now GKT School of Medical Education as Senior Lecturer, and Honorary Consultant Physician at King's College Hospital where he established the Acute Stroke Unit. In 1998, he moved to the University of Nottingham as Stroke Association Professor of Stroke Medicine, and Head of the Division of Stroke Medicine.[4] His Division was integrated into the former Division of Clinical Neuroscience in 2013, which he headed until 2021; Academic Stroke is now part of Mental Health & Clinical Neuroscience.[5] He is an Honorary Consultant Physician at Nottingham University Hospitals NHS Trust.

### Research

[edit]

Bath is recognised as an expert in stroke and clinical trials. His current research is focused on the hyperacute treatment and prevention of stroke. As a Clinical Trialist, he has been Chief Investigator of five phase III/IV trials: TAIST,[6] ENOS,[7] STEPS,[8] TARDIS,[9] and RIGHT-2.[10] He is Chief Investigator of the ongoing National Institute for Health Research (NIHR) HTA-funded Pharyngeal Electrical stimulation for Acute Stroke dysphagia Trial (PhEAST).[11]

## Honours

[edit]

In 2016 Bath was elected a Fellow of the Academy of Medical Sciences (FMedSci)[12] and appointed as Senior Investigator at the NIHR.[13] He is a Fellow of the European Stroke Organisation (2005) and American Heart Association (2014). He gave the Stroke Association keynote lecture in 2015.[14] He received the Feinberg Award for Excellence in Clinical Stroke from the American Heart Association in 2016,[15] and the British Pharmacological Society's Lilly Prize in 2024.[16] He has been given the President's Award from the British Association of Stroke Physicians (BASP) in 2019,[17] the President's Award from the World Stroke Organization (WSO) in 2021,[18] and the President's Award from the European Stroke Organisation (ESO) in 2023.[19]

## References

[edit]

1. ^ "Stroke Trials Unit".
2. ^ Bath, Philip M.W. (1991). Human monocyte behaviour and interactions with endothelium : aspects of physiology and pathology (Ph.D).
3. ^ Bath, Philip M. (2015). "Management of blood pressure after stroke". University of Nottingham. OCLC 1252181237.
4. ^ "Stroke".
5. ^ "Mental Health & Clinical Neuroscience".
6. ^ Bath, Philip MW; Lindenstrom, Ewa; Boysen, Gudrun; De Deyn, Peter; Friis, Pal; Leys, Didier; Marttila, Reijo; Olsson, Jan-Edwin; O'Neill, Desmond; Orgogozo, Jean-Marc; Ringelstein, Bernd; Van Der Sande, Jan-Jacob; Turpie, Alexander GG (2001). "Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial". The Lancet. 358 (9283): 702–710\. doi:10.1016/S0140-6736(01)05837-8. PMID 11551576. S2CID 40842062.
7. ^ ENOS Trial Investigators (2015). "Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial". The Lancet. 385 (9968): 617–628\. doi:10.1016/S0140-6736(14)61121-1. PMC 4343308. PMID 25465108.
8. ^ Bath, Philip M; Scutt, Polly; Love, Jo; Clave, Pere; Cohen, David; Dziewas, Rainer; Iversen, Helle K; Ledl, Christian; Ragab, Suzanne; Soda, Hassan; Warusevitane, Anushka; Woisard, Virginie; Hamdy, Shaheen (2016). "Pharyngeal electrical stimulation for treatment of dysphagia in subacute stroke: A randomized controlled trial". Stroke. 47 (6): 1562–1570\. doi:10.1161/STROKEAHA.115.012455. PMC 4878285. PMID 27165955.
9. ^ Bath, Philip M.; et al. (2018). "Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial". The Lancet. 391 (10123): 850–859\. doi:10.1016/S0140-6736(17)32849-0. PMC 5854459. PMID 29274727.
10. ^ Bath, Philip M.; et al. (2019). "Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial". The Lancet. 393 (10175): 1009–1020\. doi:10.1016/S0140-6736(19)30194-1. PMC 6497986. PMID 30738649.
11. ^ Bath, Philip (31 December 2024). "Pharyngeal Electrical stimulation for Acute Stroke dysphagia Trial (PhEAST)". Retrieved 31 December 2024.
12. ^ "Academy of Medical Sciences, Fellow Professor Philip Bath FMedSci".
13. ^ "Professor Philip Bath reappointed as NIHR Senior Investigator - The University of Nottingham". www.nottingham.ac.uk. Retrieved 5 January 2022.
14. ^ "Wither the brain after stroke - acute treatment and prevention". 3 November 2015.
15. ^ Bath, Philip M. (2016). "High Explosive Treatment for Ultra-Acute Stroke: Hype or Hope". Stroke. 47 (9): 2423–2426\. doi:10.1161/strokeaha.116.013243. PMID 27444258. S2CID 9105240.
16. ^ "British Pharmacological Society Final 2024 awards announced". 26 November 2024.
17. ^ "British & Irish Association of Stroke Physicians".
18. ^ "World Stroke Organisation".
19. ^ "European Stroke Organisation Presidential Award". 25 May 2023.